Opus Genetics, Inc. (IRD) News
Track canonical SquawkNews coverage tagged to IRD, Opus Genetics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 28 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Opus Genetics price target raised to $13 by Wedbush
EQUITY | Sep 10, 2026, 01:07 PM UTC
L
Opus Genetics price target raised to $16 by Chardan Capital
Chardan Capital raised its price target for Opus Genetics to $16.00 per share from $13.00, per TradingView News ratings actions compiled by Benzinga.
EQUITY | Sep 09, 2026, 09:50 PM UTC
L
Opus Genetics price target raised to $20.00 from $10.00 by Oppenheimer
EQUITY | Sep 09, 2026, 08:18 PM UTC
L
IRD seen talking of a PT raise to $20
MACRO | Sep 09, 2026, 07:31 PM UTC
L
Opus Genetics climbs to 52-week high after favorable study data
Shares of Opus Genetics reached a 52-week high after reporting favorable drug study data and a successful meeting with the FDA. Stock was recently up 26% to $5.46 and up about 171% this year.
REGULATION | Sep 09, 2026, 06:09 PM UTC
L
HC Wainwright maintains Opus Genetics $8.00 share price target
HC Wainwright & Co. maintained its $8.00/share price target for Opus Genetics, according to Benzinga ratings actions.
EQUITY | Sep 09, 2026, 06:00 PM UTC
M
IRD jumps more than 30% after gene therapy visual gains update
Shares of Opus Genetics (IRD) surged more than 30% Wednesday, delivering its best-ever single-day gains, after the company said a low dose of its experimental gene therapy showed meaningful improvements in visual functio
EQUITY | Sep 09, 2026, 05:19 PM UTC
M
IRD OPGX-BEST1 gene therapy data supports phase III advancement
Phase I/II OPGX-BEST1 gene therapy in BVMD and ARB reported strong safety and promising efficacy, with functional gains for all participants and structural improvements for most. FDA alignment on a composite microperimet
REGULATION | Sep 09, 2026, 04:31 PM UTC
L
IRD price target kept at $12.00 by BTIG
BTIG maintained a $12.00/share price target for IRD, according to Benzinga ratings actions.
EQUITY | Sep 09, 2026, 03:43 PM UTC
M
IRD reports positive OPGX-BEST1 Phase 1/2 results and Phase 3 plan
OPGX-BEST1 Phase 1/2 results showed meaningful visual and structural improvements in all participants, with a strong safety profile and FDA alignment on pivotal trial endpoints. Cohort 2 is over-enrolled and Phase 3 dosi
REGULATION | Sep 09, 2026, 02:43 PM UTC
M
IRD OPGX-BEST1 gene therapy data supports pivotal trial advancement
OPGX-BEST1 phase I/II in BVMD and ARB showed strong safety and promising efficacy. All participants had functional gains and most had structural improvements, with FDA alignment on a 3-decibel microperimetry endpoint and
REGULATION | Sep 09, 2026, 02:20 PM UTC
L
Chardan Capital maintains IRD price target at $13.00
Chardan Capital kept its IRD price target at $13.00 per share, according to Benzinga ratings actions.
EQUITY | Sep 09, 2026, 12:39 PM UTC
M
IRD OPGX-BEST1 gene therapy meets FDA-aligned microperimetry endpoint
IRD says Phase 1/2 low-dose OPGX-BEST1 in BVMD and ARB showed strong safety and encouraging efficacy, with 75% of evaluable participants meeting an FDA-aligned microperimetry endpoint and noted structural and functional
REGULATION | Sep 09, 2026, 11:37 AM UTC
M
Opus Genetics reports positive OPGx-BEST1 Phase 1/2 data
Opus Genetics reported positive safety and proof-of-concept results from low-dose Cohort 1 of OPGx-BEST1, with functional and structural gains in treated patients.
REGULATION | Sep 09, 2026, 11:33 AM UTC
L
IRD’s OPGX-BEST1 shows favorable Phase 1/2 safety, efficacy
OPGX-BEST1 showed favorable safety and clinically meaningful improvements in visual function and retinal structure in Phase 1/2 Cohort 1. FDA aligned on pivotal Phase 3 endpoints; Cohort 2 is over-enrolled as Phase 3 pla
REGULATION | Sep 09, 2026, 11:15 AM UTC
M
Opus Genetics reports positive OPGx-BEST1 Phase 1/2 cohort 1 data
OPGx-BEST1 showed a favorable safety and tolerability profile in cohort 1, with no serious adverse events or dose-limiting toxicities observed. All five participants showed clinically meaningful visual function improveme
REGULATION | Sep 09, 2026, 11:03 AM UTC
L
IRD: Opus Genetics cites positive Cohort 1 low-dose Phase 1/2 data
Opus Genetics reported positive low-dose Cohort 1 data from Phase 1/2 trial of OPGx-BEST1 and a successful FDA Type C meeting.
REGULATION | Sep 09, 2026, 11:00 AM UTC
M
IRD reports $98.6M FY26 loss after $96.5M CEIP impairment
IRD says a $96.5M non-cash CEIP impairment drove a $98.6M FY26 loss, with revenue sharply down and net assets falling 72%. Management highlights cost control and preserving project optionality, including Mulgathing explo
EQUITY | Sep 09, 2026, 07:42 AM UTC
L
Opus Genetics to present OPGx-BEST1 Cohort 1 topline data
Topline Phase 1/2 Cohort 1 data from the OPGx-BEST1 gene therapy program will be presented on Sept. 9 at 8:00 a.m. ET in an investor webcast and conference call.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
IRD - Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences - Cli
IRD - Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
Opus Genetics reports inducement grants under Nasdaq Rule 5635(c)(4)
Opus Genetics (IRD) reports inducement grants under Nasdaq Listing Rule 5635(c)(4), as disclosed in its filing under the company’s compliance reporting.
REGULATION | Aug 19, 2026, 08:01 PM UTC
L
IRD - Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
IRD - Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
EARNINGS | Aug 06, 2026, 11:00 AM UTC
M
IRD Completes Patient Enrollment in Phase 3 Trial
IRD completes enrollment in OPGx-LCA5 trial
EQUITY | Aug 03, 2026, 11:00 AM UTC
H
Analysts Initiate Buys
Analysts initiate buy ratings
EQUITY | Jul 29, 2026, 11:15 AM UTC
L
Opus Genetics sets September timeline for retinal disease trial data
Opus Genetics sets September timeline for retinal disease trial data
EQUITY | Jul 09, 2026, 01:13 PM UTC
L
Opus Genetics Unlocks Key Milestone With US FDA Alignment on OPGx-LCA5 Phase 3, Wedbush Says
() -- Opus Genetics' (IRD) alignment with the US Food and Drug Administration on the design of the registrational phase 3 study of OPGx-LCA5, an investigational gene therapy for a rare inherited retinal disease, marks an
REGULATION | Jul 06, 2026, 07:00 PM UTC
L
Sector Update: Healthcare Stocks Mixed Premarket Monday
() -- Healthcare stocks were mixed premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.4% lower and the iShares Biotechnology ETF (IBB) up 0.3%. Novartis (NVS) stock was down more than 1% a
MNA | Jul 06, 2026, 01:18 PM UTC
L
Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 F
Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elements of the trial. The Phase 3 study is expected to enroll eight participants who are able to complete microperimetry test
REGULATION | Jul 06, 2026, 11:12 AM UTC